7
Participants
Start Date
February 28, 2024
Primary Completion Date
February 28, 2026
Study Completion Date
September 30, 2026
mirabegron
"Participants will receive mirabegron prolonged-release microgranula-based oral suspension once daily. The initial dose of mirabegron will be based on the participant's weight.~The initial low dose will be up-titrated to a higher dose at weeks 2, 4 or 8 unless the participant is determined to be effectively treated with the low dose, based on urodynamics and the participants'e-diary."
Site BE32001, Edegem
Site DE49002, Hanover
Site PH63001, Quezon
Site PH63002, Quezon City
Site PL48001, Gdansk
Site TR90002, Ankara
Site TR90001, Mersin
Astellas Pharma Global Development, Inc.
INDUSTRY